ICICI Prudential Asset Management Co Ltd Sells 5,181 Shares of Amgen Inc. $AMGN

ICICI Prudential Asset Management Co Ltd trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 16.1% during the fourth quarter, HoldingsChannel reports. The firm owned 27,086 shares of the medical research company’s stock after selling 5,181 shares during the quarter. Amgen comprises 1.0% of ICICI Prudential Asset Management Co Ltd’s portfolio, making the stock its 28th largest holding. ICICI Prudential Asset Management Co Ltd’s holdings in Amgen were worth $8,866,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Dogwood Wealth Management LLC boosted its position in shares of Amgen by 275.0% during the fourth quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company’s stock worth $25,000 after purchasing an additional 55 shares in the last quarter. Anfield Capital Management LLC boosted its position in shares of Amgen by 1,000.0% during the fourth quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company’s stock worth $25,000 after purchasing an additional 70 shares in the last quarter. Board of the Pension Protection Fund bought a new position in shares of Amgen during the fourth quarter worth $26,000. Manning & Napier Advisors LLC boosted its position in shares of Amgen by 49.2% during the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company’s stock worth $32,000 after purchasing an additional 32 shares in the last quarter. Finally, Olistico Wealth LLC bought a new position in shares of Amgen during the fourth quarter worth $33,000. 76.50% of the stock is owned by institutional investors.

Amgen Trading Up 4.8%

Shares of NASDAQ:AMGN opened at $354.06 on Friday. Amgen Inc. has a 12 month low of $267.83 and a 12 month high of $391.29. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The company’s fifty day simple moving average is $340.94 and its 200 day simple moving average is $345.65. The firm has a market cap of $191.09 billion, a price-to-earnings ratio of 24.64, a PEG ratio of 3.39 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a net margin of 20.96% and a return on equity of 137.41%. The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same period in the previous year, the business earned $4.90 EPS. The company’s revenue was up 5.8% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, research analysts forecast that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Insider Transactions at Amgen

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of Amgen stock in a transaction on Monday, May 4th. The shares were sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. The trade was a 15.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.85% of the company’s stock.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen presented new Phase 3 VESALIUS-CV data showing Repatha significantly reduced cardiovascular risk in high-risk diabetes patients, strengthening the case for its cardio-metabolic franchise. Here is Why Amgen (AMGN) is One of the Top Large Cap Value Stocks to Buy Now
• Positive Sentiment: Investor coverage remains bullish, with articles highlighting Amgen as a potential value stock and pointing to attractive valuation metrics versus expected earnings growth. Is Amgen Inc. (AMGN) A Good Stock To Buy Now?
• Positive Sentiment: Amgen updated investors on its Phase 3 MARITIME-SWITCH trial, which targets GLP-1 switchers in obesity, supporting its strategy to win share in a rapidly expanding market. Amgen’s MARITIME-SWITCH Trial Targets GLP-1 Switchers in the Growing Obesity Drug Market
• Neutral Sentiment: Several market commentary pieces discussed Amgen as a large-cap value or healthcare exposure idea, but these are mostly sentiment-driven rather than immediate fundamentals. Healthcare ETFs: From Broad Exposure to Big Breakthroughs
• Negative Sentiment: Recent trading-day coverage noted Amgen underperformed the broader market, suggesting some short-term profit-taking or volatility even as the longer-term story improves. Amgen Inc. stock underperforms Wednesday when compared to competitors

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Piper Sandler dropped their price objective on shares of Amgen from $432.00 to $427.00 and set an “overweight” rating on the stock in a report on Thursday, May 14th. UBS Group raised their price objective on shares of Amgen from $390.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, April 13th. Leerink Partners restated a “market perform” rating and set a $355.00 price objective on shares of Amgen in a report on Thursday, March 5th. Guggenheim dropped their price objective on shares of Amgen from $351.00 to $340.00 and set a “neutral” rating on the stock in a report on Monday, May 4th. Finally, Jefferies Financial Group assumed coverage on shares of Amgen in a report on Tuesday, March 10th. They set a “hold” rating and a $350.00 price objective on the stock. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have issued a Hold rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $354.12.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.